|Bid||44.50 x 800|
|Ask||44.55 x 2000|
|Day's Range||44.52 - 44.81|
|52 Week Range||39.42 - 50.65|
|PE Ratio (TTM)||10.25|
|Forward Dividend & Yield||1.64 (3.66%)|
|1y Target Est||N/A|
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.
Co-founder John Hood leveraged the blood-disease therapy after finding that safety concerns that had clouded its future were largely overblown.
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
France's Sanofi (SASY.PA) and U.S Regeneron (REGN.O) said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers. In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the United States and Europe to treat eczema and undergoing tests to help treat asthma, nasal polyps, eosinophilic esophagitis and food allergies. "The investment in cemiplimab will be increased to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement and Sanofi and Regeneron will continue to equally fund cemiplimab development," the two groups said.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type ...
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
Sanofi’s recent disclosure of safety problems with the world’s only approved vaccine against the dengue has complicated efforts to contain a growing global epidemic, public-health experts say.
French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals. Under the agreement, Sanofi will obtain global development and commercialization rights to fitusiran, currently in development for the treatment of people with hemophilia A and B. Global commercialization of fitusiran will be done by Sanofi Genzyme, the specialty care global business unit of Sanofi, while Alnylam will receive royalties based on net sales of fitusiran products.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.
PARIS (Reuters) - France's Sanofi (SASY.PA) said on Thursday it would continue to cooperate with the Philippines' Food and Drug Administration after the country suspended clearance for its controversial ...
MANILA (Reuters) - The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, ...
As of December 20, 2017, of the three analysts tracking Sanofi ADR, one analyst recommends a “buy,” while two recommend a “hold.”
Sanofi’s (SNY) diabetes and cardiovascular portfolio reported revenues of 1.67 billion euros for 3Q17, representing a 9.1% YoY fall in operating revenues.
Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.
Sanofi’s (SNY) established prescription products reported revenues of 2.26 billion euros in 3Q17, representing a 6.5% YoY fall in operating revenues.
Sanofi's genzyme business reported revenues of 1.63 billion euros in 3Q17, representing a 12.5% YoY (year-over-year) rise in operating revenues.
Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).